The Strategic Capital Reallocation and Health Innovation Act

Generated by Optimitron OBG + Gemini (search-grounded structured research packet) Based on OECD efficient frontier (28 countries, rank 27/28) Category: Military | Overspend: 5.3x | US Rank: 27/28

Proposed bill title: The Strategic Capital Reallocation and Health Innovation Act

Summary

A bill to reallocate $615 billion in inefficient military overspend toward high-multiplier health research and development. It establishes a Decentralized Framework for Drug Assessment (dFDA) to leverage pragmatic trials, reducing Phase 2/3 clinical trial costs by 44x. To ensure political viability and prevent regulatory capture, the legislation funds Incentive Alignment Bonds (IABs) to compensate displaced defense workers and out-compete entrenched defense lobbying.

Findings

• The Swiss Arbitrage and Dysfunction Premium: The US pays a 3% GDP 'dysfunction premium' for 6.5 fewer years of life expectancy compared to Switzerland. US military spending efficiency ranks 27 out of 28 OECD countries. 1 2
• Macroeconomic Portfolio Inversion: Reallocating capital from military spending to healthcare investment yields a 7.16x multiplier on economic growth. Healthcare investment has a 4.3x multiplier compared to a 0.6x multiplier for military spending. 3 4
• The 44x Pragmatic Trial Leverage Point: The primary bottleneck in health innovation is the $1.56B Phase 2/3 cost barrier. Decentralized pragmatic trials can reduce per-patient costs from $41,000 to $929, a 44x reduction, bypassing the inefficient NIH grant system. 5 6

Purpose

To close the 6.5-year life expectancy gap between the United States and peer nations like Switzerland by shifting federal capital from low-ROI military spending (0.6x multiplier) to high-ROI health R&D (4.3x multiplier), while utilizing market mechanisms, pragmatic trials, and public-choice-informed compensation to overcome entrenched political opposition.

Public-Goods and Market Framework

• Health R&D as a Core Public Good: Basic and translational health research, particularly the data generated by clinical trials, is non-rivalrous and non-excludable once published. The current market fails to produce sufficient cures because the $1.56B Phase 2/3 cost barrier acts as an artificial monopoly moat. By subsidizing the trial infrastructure (dFDA) rather than the end product, the government corrects a massive market failure. 3

Public Choice / Capture Analysis

• Outgunning the Defense Lobby: Optimal policy often fails due to concentrated opposition. The defense industry spends approximately $127M annually on lobbying. This legislation explicitly sizes a buyout mechanism—Incentive Alignment Bonds funded at $2.72B annually—to outgun entrenched defense contractors 21-to-1, ensuring the reallocation survives political capture. 7 8

Pareto / Compensation Analysis

• Compensated Pareto: The reallocation of $615B from the military creates concentrated losers in the defense industrial base. To achieve a compensated Pareto improvement, the bill uses Incentive Alignment Bonds and transition funds to compensate these workers and communities. Likely losers: Defense contractors, Defense industry workers, Communities heavily reliant on military bases or manufacturing. 7 Compensation mechanism: Incentive Alignment Bonds (IABs) and targeted economic transition assistance.

Key Provisions

Establishment of the Decentralized Framework for Drug Assessment (dFDA)

Summary: Creates an alternative regulatory and funding pathway for drug efficacy testing using decentralized, pragmatic clinical trials, bypassing traditional NIH and FDA bottlenecks. 6 11 Modeled on: Singapore 3M Health System (market mechanisms), NIH Health Care Systems Research Collaboratory

Market mechanism: Open-protocol pragmatic trials where clinical sites compete on cost-per-patient data delivery, utilizing existing electronic health records. Public-goods justification: Basic and translational health R&D is a non-rivalrous, non-excludable public good that is underfunded by private markets due to the $1.56B Phase 2/3 cost barrier. Public-choice rationale: Bypasses the NIH, which allocates only 3.3% of its budget to clinical trials due to academic capture, and avoids subsidizing the $1.2T inefficient healthcare delivery sector. Pareto status: Public-Goods Exception Pareto rationale: While traditional clinical research organizations (CROs) may lose market share, the massive public health benefits and acceleration of the therapeutic pipeline justify the disruption. Compensation mechanism: None for CROs; market competition will drive transition. Residual rent handling: Trial data must be open-access; funding is tied strictly to patient enrollment and verified data delivery, capping administrative overhead.

Capture risks:

• Traditional pharmaceutical companies lobbying to maintain high trial costs as a barrier to entry. 6 11
• NIH attempting to absorb dFDA funding into traditional grant mechanisms.

Anti-capture safeguards:

• Statutory firewall separating dFDA funding from NIH appropriations. 6 11
• Mandatory acceptance of dFDA pragmatic trial data by the FDA for efficacy approvals.

Corruption risks:

• Falsification of electronic health record data to inflate patient enrollment numbers. 6 11

Anti-corruption safeguards:

• Cryptographic auditing of EHR data streams. 6 11
• Bounty system for whistleblowers reporting data fraud.

Operative clauses:

• The Secretary of HHS shall establish the dFDA as an independent agency.
• The FDA shall amend its regulations to accept pragmatic trial data meeting dFDA standards as sufficient for Phase 3 efficacy demonstration.

Expected impacts:

• Phase 3 Cost per Patient: $929. Based on NIH Collaboratory pragmatic trial averages. 6

Implementation timeline: dFDA established within 12 months; first pragmatic trial protocols launched within 24 months.

Objections and responses:

• Objection: Pragmatic trials lack rigorous controls and may miss rare adverse events. Response: Pragmatic trials utilize vastly larger sample sizes, increasing statistical power to detect rare events in real-world populations. 6

Military Overspend Reallocation and Incentive Alignment Bonds

Summary: Reduces military spending by $615B annually to match OECD efficiency floors, reallocating funds to health R&D. Allocates $2.72B annually to Incentive Alignment Bonds to compensate displaced defense workers and out-compete defense lobbying. 7 8 Modeled on: Trade Adjustment Assistance (TAA), Social Impact Bonds

Market mechanism: Bonds pay out based on the successful reduction of military overspend and the transition of defense manufacturing capacity to civilian/medical technology. Public-goods justification: Overcoming entrenched political dysfunction to reallocate capital to high-multiplier public goods requires explicit buyout mechanisms. Public-choice rationale: Defense lobbying ($127M/yr) blocks efficient capital allocation. IABs ($2.72B/yr) outgun this lobbying 21-to-1, aligning political and economic incentives with reform. Pareto status: Compensated Pareto Pareto rationale: Defense contractors and workers lose revenue/jobs, but are explicitly compensated via IABs and transition funds, making them whole while society benefits from health R&D. Compensation mechanism: Incentive Alignment Bonds and direct transition assistance for displaced defense sector workers and communities. Residual rent handling: IAB payouts are strictly formulaic, based on verified reductions in DoD spending and local economic indicators, preventing discretionary slush funds.

Capture risks:

• Defense contractors capturing the IAB payouts without actually reducing lobbying or transitioning capacity. 7 8

Anti-capture safeguards:

• IAB payouts are contingent on statutory reductions in DoD appropriations. 7 8
• Strict clawback provisions if lobbying activities continue.

Corruption risks:

• Politicians directing IAB funds to favored districts regardless of actual defense displacement. 7 8

Anti-corruption safeguards:

• Algorithmic distribution of IABs based on historical defense contract concentration. 7 8
• Independent auditing by the GAO.

Operative clauses:

• DoD baseline budget shall be reduced by $615B annually, phased over 5 years.
• The Treasury shall issue $2.72B annually in Incentive Alignment Bonds.

Expected impacts:

• Defense Lobbying Influence: Neutralized. IAB funding outguns defense lobbying 21.4x. 7

Implementation timeline: DoD budget reductions begin in FY+1; IAB issuance begins immediately upon enactment.

Objections and responses:

• Objection: Paying off defense contractors borders on legalized bribery. Response: It is a mathematically sized buyout of concentrated opposition, a necessary public-choice mechanism to achieve a $564B net annual societal benefit. 7

Reallocation Plan

• The $615B Macroeconomic Inversion: The bill reallocates $615B annually from the Department of Defense. $564B is directed to the Decentralized Framework for Drug Assessment (dFDA) to fund pragmatic trials. The remaining funds are allocated to Incentive Alignment Bonds and deficit reduction, avoiding the $1.2T waste in existing healthcare delivery systems. 4 9

Fiscal Impact

• Net Positive Fiscal and Economic Impact: The legislation is deficit-neutral or deficit-reducing. It cuts $615B in low-multiplier (0.6x) military spending and invests in high-multiplier (4.3x) health R&D. The net economic growth is projected to significantly increase federal tax revenues over a 10-year window. 3 4

Implementation Timeline

• Phased Reallocation and dFDA Spin-Up: Year 1: Establish dFDA and issue initial IABs. Year 2-5: Phased 20% annual reductions in DoD overspend, with corresponding increases in dFDA pragmatic trial funding. Year 6+: Full $615B reallocation achieved. 6

Evaluation & Sunset Provisions

• Phase 3 Clinical Trial Cost per Patient: < $1,500. To verify the 44x cost reduction of pragmatic trials compared to traditional Phase 3 trials. 5 6
• US Life Expectancy: 80.0 years within 10 years. To close the 6.5-year gap with Switzerland (84.0 years) by shifting capital to high-leverage health R&D. 10 2
• Defense Lobbying Expenditures: 50% reduction in anti-reallocation lobbying. To measure the effectiveness of Incentive Alignment Bonds in neutralizing entrenched opposition to the reallocation. 7

Evidence Appendix

• Healthcare investment economic multiplier: Healthcare investment has an economic multiplier of 4.3x, significantly higher than military spending. 3
• Military spending economic multiplier: Military spending has an economic multiplier of only 0.6x, acting as a drag on the broader economy. 4
• Health Care Spending in the United States: The US wastes approximately $1.2T annually on healthcare inefficiency, necessitating that new funds bypass existing delivery systems. 9

Open Questions

• What specific statutory definitions are required to legally separate 'curative R&D' from 'symptomatic treatment' to prevent regulatory capture of the new funds?
• How can Incentive Alignment Bonds be structured to comply with current FEC regulations and anti-corruption statutes while still providing binding commitments?
• What specific transition costs and severance requirements are needed for defense industry workers displaced by a $615B cut to military overspend?

---

Sources

1. data.oecd.org
2. who.int
3. pmc.ncbi.nlm.nih.gov
4. mercatus.org
5. ncbi.nlm.nih.gov
6. commonfund.nih.gov
7. opensecrets.org
8. opensecrets.org
9. jamanetwork.com
10. cdc.gov
11. pmc.ncbi.nlm.nih.gov

---

Metadata

• Search queries:
• Sources cited: 11
• Claims with citations: 21
• Rendered bill title: The Strategic Capital Reallocation and Health Innovation Act
• Structured research model: gemini-3.1-pro-preview
• Structured findings: 3
• Structured provisions: 2
• Structured evaluation metrics: 3
• Evidence bundle model: gemini-3.1-pro-preview
• Evidence bundle parameters: 27
• Evidence bundle insights: 5
• Evidence bundle summary: To draft federal legislation that moves the US toward Switzerland's life expectancy and efficiency, lawmakers must recognize that the US pays a 3% GDP 'dysfunction premium' for 6.5 fewer years of life. The optimal strategy is a macroeconomic portfolio inversion: reallocating the $615B military overspend (0.6x multiplier) to health R&D (4.3x multiplier). However, this capital must bypass the inefficient NIH and existing healthcare delivery systems ($1.2T waste). Instead, it should fund a Decentralized Framework for Drug Assessment (dFDA) to utilize pragmatic trials, reducing the Phase 2/3 cost bottleneck by 44x. Crucially, the legislation must be public-choice realistic, utilizing ~10% of the savings to fund Incentive Alignment Bonds (IABs) that outgun defense lobbying 21-to-1, ensuring the reform survives political capture.
• Category: Military
• Model country: Switzerland
• Overspend ratio: 5.3x
• Potential savings: $564B/yr
• Related OPG policy briefs: Military: Adopt Switzerland's Approach (reallocate, grade B)